[{"id":"7e6819a5-0a0e-4ce4-b697-04b501a41ea6","acronym":"GT-30","url":"https://clinicaltrials.gov/study/NCT04251117","created_at":"2024-04-19T18:51:54.179Z","updated_at":"2025-02-25T17:24:31.308Z","phase":"Phase 1/2","brief_title":"GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC","source_id_and_acronym":"NCT04251117 - GT-30","lead_sponsor":"Geneos Therapeutics","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • rocakinogene sifuplasmid (INO-9012) • GNOS-PV02"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/01/2020","start_date":" 03/01/2020","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2028","study_completion_date":" 11/29/2028","last_update_posted":"2025-01-31"},{"id":"154afa1b-c0be-412f-b05f-4aaae6570e78","acronym":"","url":"https://clinicaltrials.gov/study/NCT04015700","created_at":"2021-01-18T19:43:25.060Z","updated_at":"2024-07-02T16:35:15.562Z","phase":"Phase 1","brief_title":"Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma","source_id_and_acronym":"NCT04015700","lead_sponsor":"Washington University School of Medicine","biomarkers":" IDH1 • IDH2 • MGMT","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 07/14/2020","start_date":" 07/14/2020","primary_txt":" Primary completion: 05/13/2022","primary_completion_date":" 05/13/2022","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-08"},{"id":"37ba8d01-7c78-43cc-81e1-59e78827f9d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04367675","created_at":"2021-01-18T21:06:34.302Z","updated_at":"2024-07-02T16:35:32.189Z","phase":"Phase 1b","brief_title":"INO 5401 Vaccination in BRCA1/2 Mutation Carriers","source_id_and_acronym":"NCT04367675","lead_sponsor":"University of Pennsylvania","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INO-5401 • rocakinogene sifuplasmid (INO-9012)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-23"},{"id":"97e099ff-5286-4e2a-86a3-91ea5e73a0b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03439085","created_at":"2021-01-29T07:16:58.643Z","updated_at":"2024-07-02T16:36:17.195Z","phase":"Phase 2","brief_title":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers","source_id_and_acronym":"NCT03439085","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • rocakinogene sifuplasmid (INO-9012) • INO-3112"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 11/14/2018","start_date":" 11/14/2018","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-02-14"},{"id":"337d5bf7-588a-4338-b1ad-206b4cae5557","acronym":"","url":"https://clinicaltrials.gov/study/NCT02241369","created_at":"2021-06-23T19:53:14.793Z","updated_at":"2024-07-02T16:37:05.237Z","phase":"Phase 1","brief_title":"Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies","source_id_and_acronym":"NCT02241369","lead_sponsor":"Inovio Pharmaceuticals","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rocakinogene sifuplasmid (INO-9012) • INO-3106"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2018-11-16"},{"id":"13f962ad-4e51-40e4-943d-c2f1a42f8f88","acronym":"","url":"https://clinicaltrials.gov/study/NCT02327468","created_at":"2021-01-18T11:02:43.451Z","updated_at":"2024-07-02T16:37:16.072Z","phase":"Phase 1","brief_title":"Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers","source_id_and_acronym":"NCT02327468","lead_sponsor":"Inovio Pharmaceuticals","biomarkers":" PGR • CD8 • PTPRC • FOXP3","pipe":" | ","alterations":" HER-2 negative","tags":["PGR • CD8 • PTPRC • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rocakinogene sifuplasmid (INO-9012) • INO-1400"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 04/01/2018","study_completion_date":" 04/01/2018","last_update_posted":"2017-11-24"}]